Complementary discoveries have the potential to enhance treatment options for antibiotic-resistant infections. Researchers at ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

As translational CRISPR-based research continues to make waves in laboratories and the clinic, scientists across life science disciplines pursue out-of-the-ordinary genome editing applications. From ...

Exchange Traded Concepts LLC trimmed its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 16.0% during the fourth quarter, according to the company in its most recent Form ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $41.21, denoting a -1.44% change from the preceding trading day.